Equities analysts forecast that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will report earnings per share (EPS) of ($1.28) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.16). Tonix Pharmaceuticals reported earnings per share of ($8.80) during the same quarter last year, which would suggest a positive year-over-year growth rate of 85.5%. The company is expected to report its next quarterly earnings report on Monday, May 13th.

On average, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($3.99) per share for the current year, with EPS estimates ranging from ($4.00) to ($3.97). For the next year, analysts anticipate that the business will report earnings of ($1.99) per share, with EPS estimates ranging from ($2.37) to ($1.60). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Tonix Pharmaceuticals.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, March 18th. The company reported ($6.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.66) by ($2.44).

Separately, Roth Capital raised Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Thursday, April 18th.

TNXP stock traded down $0.03 during trading on Tuesday, hitting $2.31. The company had a trading volume of 732,300 shares, compared to its average volume of 1,371,143. The firm has a market cap of $14.25 million, a price-to-earnings ratio of -0.09 and a beta of 1.91. Tonix Pharmaceuticals has a fifty-two week low of $1.70 and a fifty-two week high of $51.10.

In related news, CEO Seth Lederman purchased 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were acquired at an average price of $2.38 per share, with a total value of $59,500.00. Following the purchase, the chief executive officer now directly owns 1,767 shares in the company, valued at $4,205.46. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.07% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of TNXP. Bank of New York Mellon Corp acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $38,000. CVI Holdings LLC acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $36,000. Finally, Citigroup Inc. acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $34,000. 8.58% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

See Also: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Tonix Pharmaceuticals (TNXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.